Trial Profile
A first-of-its-kind comprehensive clinical study for the treatment of macular degeneration using Stemedica's MCT (Multiple Cell Technology) adult stem cells and the Lumenis SRT laser
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2014
Price :
$35
*
At a glance
- Drugs Retinal pigment epithelial cell replacement therapy-Stemedica Cell Technologies (Primary)
- Indications Macular degeneration
- Focus Adverse reactions
- 16 Jun 2014 New trial record